AstraZeneca PLC And Bristol-Myers Squibb Company Diabetes Alliance Provides $5 Million Grant For American Diabetes Association's Pathway to Stop Diabetes Research Initiative

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WILMINGTON, Del. & PRINCETON, N.J.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies’ U.S. Diabetes Alliance is providing a three-year grant to the American Diabetes Association’s Pathway to Stop Diabetes program. The innovative research initiative provides resources and support for a new generation of diabetes researchers and is designed to generate exciting discoveries through excellence, innovation, collaboration and radical thinking.

Help employers find you! Check out all the jobs and post your resume.

Back to news